Business Description
Actinium Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00507W2061
Total Employee Number:
25Compare
Compare
Traded in other countries / regions
ATNM.USA7AY1.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2007-07-19Description
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 27.74 | |||||
Equity-to-Asset | 0.05 | |||||
Debt-to-Equity | 0.66 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -13.17 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -58.8 | |||||
3-Year EBITDA Growth Rate | 6.4 | |||||
3-Year EPS without NRI Growth Rate | 7.3 | |||||
3-Year Book Growth Rate | -54.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 38.68 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 25.95 | |||||
9-Day RSI | 32 | |||||
14-Day RSI | 34.86 | |||||
3-1 Month Momentum % | -18.18 | |||||
6-1 Month Momentum % | -23.26 | |||||
12-1 Month Momentum % | -44.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.89 | |||||
Quick Ratio | 5.89 | |||||
Cash Ratio | 5.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.7 | |||||
Shareholder Yield % | 0.85 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -28346.67 | |||||
Net Margin % | -26078.89 | |||||
EBITDA Margin % | -27417.78 | |||||
FCF Margin % | -25420 | |||||
OCF Margin % | -25417.78 | |||||
ROE % | -171 | |||||
ROA % | -41.17 | |||||
ROIC % | -924.95 | |||||
3-Year ROIIC % | 339.08 | |||||
ROC (Joel Greenblatt) % | -1437.3 | |||||
ROCE % | -51.55 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 284.81 | |||||
PB Ratio | 12.21 | |||||
Price-to-Tangible-Book | 12.21 | |||||
EV-to-EBIT | 0.54 | |||||
EV-to-Forward-EBIT | 1.99 | |||||
EV-to-EBITDA | 0.56 | |||||
EV-to-Forward-EBITDA | 0.75 | |||||
EV-to-Revenue | -153.44 | |||||
EV-to-Forward-Revenue | 5128.84 | |||||
EV-to-FCF | 0.6 | |||||
Earnings Yield (Greenblatt) % | 185.19 | |||||
FCF Yield % | -85.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:ATNM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Actinium Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.09 | ||
| EPS (TTM) ($) | -0.75 | ||
| Beta | 0.2007 | ||
| 3-Year Sharpe Ratio | -0.61 | ||
| 3-Year Sortino Ratio | -0.79 | ||
| Volatility % | 44.33 | ||
| 14-Day RSI | 34.86 | ||
| 14-Day ATR ($) | 0.049216 | ||
| 20-Day SMA ($) | 0.931605 | ||
| 12-1 Month Momentum % | -44.69 | ||
| 52-Week Range ($) | 0.8068 - 1.8059 | ||
| Shares Outstanding (Mil) | 31.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Actinium Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Actinium Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-26 09:30 | In 122 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 108 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 10 days | ||
| First quarter earnings results for 2026 | 2026-05-08 | 1.22 (-0.81%) | ||
| Annual report for 2026 | 2026-03-30 | 1.03 (+0.00%) | ||
| General meeting for 2025 | 2025-11-26 09:30 | 1.40 (+1.45%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.25 (-3.85%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 1.56 (-4.29%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 1.43 (+2.88%) | ||
| Annual report for 2025 | 2025-03-31 | 1.81 (-7.65%) |
Show
Entries
Actinium Pharmaceuticals Inc Frequently Asked Questions
What is Actinium Pharmaceuticals Inc(ATNM)'s stock price today?
The current price of ATNM is $0.85. The 52 week high of ATNM is $1.81 and 52 week low is $0.81.
When is next earnings date of Actinium Pharmaceuticals Inc(ATNM)?
The next earnings date of Actinium Pharmaceuticals Inc(ATNM) is 2026-08-07 Est..
Does Actinium Pharmaceuticals Inc(ATNM) pay dividends? If so, how much?
Actinium Pharmaceuticals Inc(ATNM) does not pay dividend.
Guru Commentaries on AMEX:ATNM
No articles.
Press Release
Articles on Actinium Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers